Rethinking the Prostate Cancer Paradigm in the Urology Community

The urology community is deficient in identifying the patient with advanced prostate cancer who is at risk of developing metastatic disease. The failure of the urologist, as well as the medical oncologist, to understand the limitations and usefulness of PSA, especially in the setting of the patient on androgen deprivation therapy (ADT), has led to delays in identification of metastases and subsequent institution of superior therapies.

Read more.